Why Defense Health Innovation Is Shaping the Future of Medicine
Explore how military medicine, dual-use technologies, and national security investments are accelerating breakthroughs that ultimately improve civilian healthcare.
Healthcare strategy that bridges the gap between scientific discovery and real-world adoption.
Innovation only matters when it reaches patients.
A running record of panels, podcasts, and stages — from cannabis policy to defense health innovation.
Panel: Legalized Possession and Use of Cannabis — A Legal and Ethical Dilemma for Healthcare Organizations.
Panelists: Richard Cheng (Weaver Johnson & Nelson, PLLC), Dr. Darina A. Douchi (CEO & Founder, Curativo Enterprises, LLC), Eric S. Gaines (moderator; Baylor Scott & White Health Enterprise), Robert Head (Hemp for Victory), and W. Stephen Love (Dallas-Fort Worth Hospital Council).
Invited by founder Sophia to share her personal story — topic open.
First Annual Women's Wellness Summit — built around the 5 M's: Mental Health, Metabolic Health, Motherhood, Menopause, and Money.
A conference curated for family offices, private equity firms, and UHNWIs.
Explore how military medicine, dual-use technologies, and national security investments are accelerating breakthroughs that ultimately improve civilian healthcare.
Examine how defense health innovation intersects with regulated therapeutics — including cannabis, psychedelics, and other emerging therapies — and why this convergence matters for healthcare, investment, and policy.
Examine how technologies developed for military readiness transition into civilian medicine, and what barriers still prevent wider adoption.
Explore how military human performance initiatives are influencing preventive medicine, rehabilitation, resilience, and healthy aging.
Explain how digital twins may transform personalized care, clinical decision support, disease prediction, healthcare operations, and pharmaceutical development.
Show why cybersecurity is no longer just an IT responsibility but a core component of clinical safety, operational continuity, and trust in digital healthcare.
Examine the shift toward decentralized care, remote monitoring, AI-enabled decision support, and home-based healthcare.
Discuss interoperability, FHIR, AI, cloud platforms, cybersecurity, and digital biomarkers as foundational infrastructure rather than isolated technologies.
Argue that AI alone cannot transform healthcare without secure, interoperable, data-driven infrastructure to support it.
Examine how cannabis, psychedelic-assisted therapies, ketamine, peptides, and future regulated therapeutics are reshaping clinical practice, reimbursement, regulation, and investment.
Provide an evidence-based overview of peptide therapies, their expanding clinical applications, regulatory landscape, commercialization opportunities, and future role in precision medicine.
Move beyond political debates to examine cannabis through the lens of healthcare delivery, regulation, patient outcomes, reimbursement, and implementation.
Explore the infrastructure, education, regulation, and clinical standards necessary for responsible adoption of psychedelic-assisted therapies.
Discuss the systems needed to support regulated therapeutics, including education, clinical protocols, interoperability, outcomes tracking, reimbursement, and compliance.
Explore the scientific, clinical, economic, and policy implications of longevity medicine and healthy aging, with a focus on improving quality of life rather than simply extending lifespan.
Examine how precision medicine influences healthcare economics, commercialization, reimbursement, research, and patient engagement.
Explain how digital biomarkers enable earlier detection, continuous monitoring, and more personalized clinical decision-making.
Examine how promising innovations move from research to real-world adoption, including commercialization strategy, reimbursement, market access, and partnerships.
Share a framework for evaluating healthcare companies beyond technology by assessing commercialization readiness, regulatory pathways, reimbursement strategy, execution risk, and market fit.
Explain how family offices can evaluate opportunities in healthcare by understanding clinical validation, commercialization, regulatory risk, and long-term market potential.
Analyze the non-technical reasons healthcare innovations fail, including commercialization, reimbursement, implementation, regulatory barriers, and adoption challenges.
Explain how federal grants, contracts, and public-private partnerships help healthcare innovators reduce risk and accelerate commercialization.
Provide an overview of SBIR/STTR, ARPA-H, NIH, BARDA, DoD, VA, and other federal funding opportunities supporting healthcare innovation.
Explain what healthcare companies should know before entering government markets, including procurement, compliance, commercialization, and contracting strategies.
Explore why women's health remains underfunded despite representing one of the largest unmet healthcare markets, and examine opportunities for innovation, investment, and policy.
Examine how AI, digital health, emerging therapeutics, precision medicine, and defense innovation can improve healthcare for women.
Analyze why investment, research, and commercialization have historically overlooked women's health and what needs to change.
Argue that successful healthcare innovation depends on commercialization, reimbursement, implementation, policy, and education — not technology alone.
Introduce a strategic framework of innovation, commercialization, investment, and policy, and explain why understanding their interaction is essential for healthcare leaders.
Define what healthcare strategy means in today's environment and provide a framework for navigating complex healthcare ecosystems.
No topics yet for this focus area.
Loading articles…